BioOhio member company STATKING Clinical Services has shared the following release.

Fairfield, OH, May 11, 2020 – STATKING Clinical Services, a Contract Research Organization (CRO) located in Cincinnati, OH is working with a pharmaceutical industry partner to develop an anti-infective drug product to treat the COVID-19 virus.  STATKING is providing clinical research services for the development of this product including biostatistical and data analysis services for the studies.  It is STATKING’s role to bring the data analysis results of these studies into a form that can be reviewed by FDA regulatory authorities for approval of the drug for use in the United States.

The company is well-positioned to provide these services as they have provided clinical study services on over 500 clinical trials for the regulatory approval of drug and medical device products.  Dr. King commented “Our team here at STATKING is excited to be part of the team of people working across the planet to combat the COVID-19 virus.  One of our core goals here at STATKING is to develop pharmaceutical and medical device products that relieve patient suffering and speed healing.  This may be one of the most important projects in the 31-year history of our company.”

About STATKING Clinical Services

STATKING Clinical Services provides clinical trial services (clinical trial management, protocol development, biostatistics, clinical data management, clinical study monitoring, medical writing, medical monitoring, safety reporting, and project management) for clinical trials for the regulatory approval of novel drug and medical device products.  The company is headquartered in Cincinnati, OH.  The company has provided support on 15 NDAs, 14 PMAs, 2 BLAs, 3 NADAs and numerous 510Ks over the past 30 years of service to the pharmaceutical, medical device and animal health industries.  For more information, visit


STATKING Clinical Services

Rod Lashley, Executive Vice President 513-858-2989 x303,